Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Bladder

The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare everolimus with respect to overall survival (OS). The hypothesis is that belzutifan is superior to everolimus with respect to PFS and OS.
Bladder
III
Beckermann, Kathryn
NCT04195750
VICCURO19114

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: